NCT03667482 is a Phase 1 clinical trial of Cabozantinib in Head and Neck Squamous Cell Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT03667482?

NCT03667482 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT03667482?

Interventions in NCT03667482: Cabozantinib, Cetuximab.

What condition does NCT03667482 study?

NCT03667482 studies Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer.

Is NCT03667482 still recruiting?

NCT03667482 is currently completed. Last updated 23 July 2024.

Last reviewed 2024-07-23 · How we verify

NCT03667482

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Completed Phase 1 Last updated 23 July 2024

What this trial tests

Phase 1 trial testing Cabozantinib in Head and Neck Squamous Cell Cancer in 20 participants. Completed in 17 July 2024.

Timeline

7 September 2018

Primary endpoint
17 July 2024

17 July 2024

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	7 September 2018
Primary completion	17 July 2024
Estimated completion	17 July 2024
Sites	9 locations across United States

Drugs / interventions tested

Cabozantinib (CABOZANTINIB) — full drug profile →
Cetuximab (cetuximab) — full drug profile →

Conditions studied

Head and Neck Squamous Cell Cancer — all drugs for Head and Neck Squamous Cell Cancer →
Recurrent Head and Neck Squamous Cell Cancer — all drugs for Recurrent Head and Neck Squamous Cell Cancer →
Metastatic Head and Neck Squamous Cell Cancer — all drugs for Metastatic Head and Neck Squamous Cell Cancer →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Head and Neck Squamous Cell Cancer or Recurrent Head and Neck Squamous Cell Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the safety of cabozantinib, at different doses, in combination with cetuximab to find out what effects, if any, this combined treatment has on people with HNSCC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

BDNF and its signaling in cancer.
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, et al · · 2023 · cited 48× · PMID 36173463 · DOI 10.1007/s00432-022-04365-8
Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
Farlow JL, Brenner JC, Lei YL, Chinn SB. · · 2021 · cited 34× · PMID 34218062 · DOI 10.1016/j.oraloncology.2021.105420
Current Insights and Progress in the Clinical Management of Head and Neck Cancer.
Amaral MN, Faísca P, Ferreira HA, Gaspar MM, et al · · 2022 · cited 32× · PMID 36551565 · DOI 10.3390/cancers14246079
Head and neck cancer: pathogenesis and targeted therapy.
Liu Y, Zhang N, Wen Y, Wen J. · · 2024 · cited 21× · PMID 39170944 · DOI 10.1002/mco2.702
Radiotherapy, Chemotherapy and Immunotherapy-Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma.
Melo-Alvim C, Neves ME, Santos JL, Abrunhosa-Branquinho AN, et al · · 2022 · cited 20× · PMID 36611391 · DOI 10.3390/diagnostics13010099
Emerging tyrosine kinase inhibitors for head and neck cancer.
Long Z, Grandis JR, Johnson DE. · · 2022 · cited 10× · PMID 36131561 · DOI 10.1080/14728214.2022.2125954
New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases.
Bensen R, Brognard J. · · 2021 · cited 10× · PMID 33799513 · DOI 10.3390/ijms22062831
Cabozantinib combination therapy for the treatment of solid tumors: a systematic review.
Castellano D, Apolo AB, Porta C, Capdevila J, et al · · 2022 · cited 6× · PMID 35923927 · DOI 10.1177/17588359221108691

Verify or expand the search:

Other trials of Cabozantinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07187869 — Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell · Phase 1 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06900595 — Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent · Phase 2 · recruiting

Other recruiting trials for Head and Neck Squamous Cell Cancer

Currently open trials in the same condition.

NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT06736379 — Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer · Phase 1 · recruiting
NCT06545331 — Study of XB010 in Subjects With Solid Tumors · Phase 1 · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03667482 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 23 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03667482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing